Published in J Allergy Clin Immunol on October 01, 1986
Phosphodiesterase inhibitors: new opportunities for the treatment of asthma. Thorax (1991) 2.17
Stimulation of the hypothalamo-pituitary-adrenal axis in the rat by the type 4 phosphodiesterase (PDE-4) inhibitor, denbufylline. Br J Pharmacol (1996) 0.80
The role of adenosine receptors in the action of theophylline on human peripheral blood mononuclear cells from healthy and asthmatic subjects. Br J Pharmacol (2000) 0.76
Theophylline therapy inhibits neutrophil and mononuclear cell chemotaxis from chronic asthmatic children. Br J Clin Pharmacol (1991) 0.76
Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med (1999) 11.44
Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol (1991) 3.01
Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol (1995) 2.89
Reduced beta-adrenoceptor sensitivity in the elderly. Clin Pharmacol Ther (1979) 2.85
Antipyrine metabolism in man: influence of age, alcohol, caffeine, and smoking. Clin Pharmacol Ther (1975) 2.64
Management of drug therapy in the elderly. N Engl J Med (1989) 2.43
Reduced subjective awareness of bronchoconstriction provoked by methacholine in elderly asthmatic and normal subjects as measured on a simple awareness scale. Thorax (1992) 2.11
Aging and ethanol metabolism. Clin Pharmacol Ther (1977) 1.99
Drug use in the elderly: a review of problems and special considerations. Drugs (1978) 1.95
Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol (1998) 1.91
Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol. Proc Natl Acad Sci U S A (1988) 1.65
Effects of age and cigarette smoking on propranolol disposition. Clin Pharmacol Ther (1979) 1.62
Direct measurement of propranolol bioavailability during accumulation to steady-state. Br J Clin Pharmacol (1978) 1.60
Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base. J Clin Oncol (1990) 1.57
Impaired bronchodilator response to albuterol in healthy elderly men and women. Chest (1995) 1.56
Effect of aging and cigarette smoking on antipyrine and indocyanine green elimination. Clin Pharmacol Ther (1979) 1.55
Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study. J Clin Oncol (1994) 1.49
Smoking and drug metabolism. Pharmacol Ther (1981) 1.45
Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label study. Br J Dermatol (2012) 1.42
Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. Am J Respir Crit Care Med (1996) 1.41
Intra-arterial thrombolysis (reteplase) and ReoPro for subacute thrombosis of the distal aorta accomplished by radial arterial access: the radial-kissing-thrombolytic technique. Catheter Cardiovasc Interv (2001) 1.39
Teniposide (VM-26) as a single drug treatment for patients with extensive small cell lung carcinoma: a Phase II study of the Southwest Oncology Group. Cancer (1997) 1.38
Biological determinants of propranolol disposition in man. Clin Pharmacol Ther (1978) 1.35
Effects of selective phosphodiesterase inhibitors on the polymorphonuclear leukocyte respiratory burst. J Allergy Clin Immunol (1990) 1.34
Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint. Control Clin Trials (2000) 1.33
Influence of the emetic reflex on vasopressin release in man. Kidney Int (1979) 1.31
Effect of intravenous aminophylline on plasma levels of catecholamines and related cardiovascular and metabolic responses in man. Circulation (1983) 1.27
Dose response effectiveness of propranolol for the treatment of angina pectoris. Circulation (1975) 1.22
A randomized trial of radiotherapy versus radiotherapy plus CCNU for incompletely resected low-grade gliomas: a Southwest Oncology Group study. J Neurosurg (1993) 1.19
Induction chemotherapy before surgery for early-stage lung cancer: A novel approach. Bimodality Lung Oncology Team. J Thorac Cardiovasc Surg (2000) 1.15
Primary renal artery stenting: characteristics and outcomes after 363 procedures. Am Heart J (2001) 1.14
The management of ovarian-cancer-caused bowel obstruction. Gynecol Oncol (1981) 1.14
Synchronous multicentric osteosarcoma: the case for metastases. Skeletal Radiol (1997) 1.11
PGG-glucan, a soluble beta-(1,3)-glucan, enhances the oxidative burst response, microbicidal activity, and activates an NF-kappa B-like factor in human PMN: evidence for a glycosphingolipid beta-(1,3)-glucan receptor. Immunopharmacology (1999) 1.10
The response of arginine vasopressin to intravenous ethanol and hypertonic saline in man: the impact of aging. J Gerontol (1978) 1.06
Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol (2011) 1.06
Varied presentations of metastatic pulmonary melanoma. Chest (1974) 1.05
Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Causes Control (2001) 1.04
Time-related increases in cardiac concentrations of doxorubicinol could interact with doxorubicin to depress myocardial contractile function. Br J Pharmacol (1993) 1.03
Residual intake and body weight gain: a new measure of efficiency in growing cattle. J Anim Sci (2011) 1.01
Female preponderance in diuretic-associated hypokalemia: a retrospective study in seven long-term care facilities. J Am Geriatr Soc (1982) 1.01
Deep resequencing and association analysis of schizophrenia candidate genes. Mol Psychiatry (2012) 1.00
A randomized controlled Alzheimer's disease prevention trial's evolution into an exposure trial: the PREADViSE Trial. J Nutr Health Aging (2013) 1.00
Long-term, low-level microwave irradiation of rats. Bioelectromagnetics (1992) 1.00
Hepatic drug metabolism and aging. Clin Pharmacokinet (1990) 0.99
Advanced bronchioloalveolar carcinoma: a phase II trial of paclitaxel by 96-hour infusion (SWOG 9714): a Southwest Oncology Group study. Ann Oncol (2005) 0.99
High-dose melphalan with autotransplantation for refractory multiple myeloma: results of a Southwest Oncology Group phase II trial. J Clin Oncol (1999) 0.98
Characterization of four homologous L chain variable region genes that are related to 6B6.6 idiotype positive human rheumatoid factor L chains. J Immunol (1989) 0.98
Active uptake of propranolol by isolated rabbit alveolar macrophages and its inhibition by other basic amines. J Pharmacol Exp Ther (1980) 0.98
Oncostatin M-specific receptor expression and function in regulating cell proliferation of normal and malignant mammary epithelial cells. Cytokine (1998) 0.97
Solitary brain metastasis: results of an RTOG/SWOG protocol evaluation surgery + RT versus RT alone. Am J Clin Oncol (1990) 0.97
CD40 is functionally expressed on human breast carcinomas: variable inducibility by cytokines and enhancement of Fas-mediated apoptosis. Breast Cancer Res Treat (1998) 0.97
Inhibition of propranolol metabolism by chlorpromazine. Clin Pharmacol Ther (1979) 0.96
Acute coronary embolism complicating aortic valve endocarditis treated with streptokinase and aspirin. A case report. J Heart Valve Dis (1994) 0.96
Phase II study of fludarabine phosphate in multiple myeloma. A Southwest Oncology Group study. Invest New Drugs (1990) 0.95
Doxorubicin cardiomyopathy is associated with a decrease in calcium release channel of the sarcoplasmic reticulum in a chronic rabbit model. J Clin Invest (1993) 0.94
A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group study. Cancer (1995) 0.93
Aging and drug interactions. I. Effect of cimetidine and smoking on the oxidation of theophylline and cortisol in healthy men. J Pharmacol Exp Ther (1987) 0.93
Surgical resection of stage IIIA and stage IIIB non-small-cell lung cancer after concurrent induction chemoradiotherapy. A Southwest Oncology Group trial. J Thorac Cardiovasc Surg (1993) 0.93
Individual and combined effects of cimetidine and ciprofloxacin on theophylline metabolism in male nonsmokers. Br J Clin Pharmacol (1993) 0.92
Acute renal toxicity with combined use of amphotericin B and cyclosporine after marrow transplantation. Transplantation (1983) 0.90
Fulminant hepatic failure following low-dose sustained-release niacin therapy in hospital. West J Med (1991) 0.90
Independent lung ventilation with a single ventilator using a variable resistance valve. Chest (1995) 0.89
Concurrent chemotherapy/radiotherapy for limited small-cell lung carcinoma: a Southwest Oncology Group Study. J Clin Oncol (1990) 0.89
Prevalence of renovascular hypertension in patients with grade III or IV hypertensive retinopathy. N Engl J Med (1979) 0.89
Interferon versus interferon plus prednisone remission maintenance therapy for multiple myeloma: a Southwest Oncology Group Study. J Clin Oncol (1998) 0.89
Acute hemodynamic changes during carotid artery stenting. Am J Cardiol (1998) 0.89
Evaluation of topotecan in resistant and relapsing multiple myeloma: a Southwest Oncology Group study. J Clin Oncol (1998) 0.89
Hazardous substances, the environment and public health: a statistical overview. Environ Health Perspect (1979) 0.88
Novel mechanism of transcriptional activation of hepatic LDL receptor by oncostatin M. J Lipid Res (1997) 0.88
Long-term survival and toxicity in small cell lung cancer. Expanded Southwest Oncology Group experience. Chest (1991) 0.87
Comparative inhibition of human cytochromes P450 1A1 and 1A2 by flavonoids. Drug Metab Dispos (1998) 0.87
Polymorphonuclear leukocyte inhibition by therapeutic concentrations of theophylline is mediated by cyclic-3',5'-adenosine monophosphate. Am Rev Respir Dis (1988) 0.87
Is phospholipase A2 activation regulated by G-proteins? Biochem Soc Trans (1991) 0.87
Effects of adenosine on polymorphonuclear leucocyte function, cyclic 3': 5'-adenosine monophosphate, and intracellular calcium. Br J Pharmacol (1989) 0.86
Daunorubicin cardiotoxicity: evidence for the importance of the quinone moiety in a free-radical-independent mechanism. Biochem Pharmacol (2000) 0.86
Southwest Oncology Group phase II trial of concurrent carboplatin, etoposide, and radiation for poor-risk stage III non-small-cell lung cancer. J Clin Oncol (1998) 0.86
Prognostic value of nucleoli and cell size in chronic lymphocytic leukemia. Am J Hematol (1978) 0.86
Proton NMR measurements of bacteriophage T4 lysozyme aided by 15N isotopic labeling: structural and dynamic studies of larger proteins. Proc Natl Acad Sci U S A (1987) 0.86
Cardiac functional responses to adenosine by PD 81,723, an allosteric enhancer of the adenosine A1 receptor. Am J Physiol (1993) 0.86
Cigarette smoking and theophylline metabolism: effects of cimetidine. Clin Pharmacol Ther (1985) 0.86
In vivo functional antagonism between isoproterenol and bronchoconstrictants in the dog. J Appl Physiol (1985) (1987) 0.86
Effects of tumor necrosis factor on PMN chemotaxis, chemiluminescence, and elastase activity. J Lab Clin Med (1989) 0.85
Species comparison of adenosine and beta-adrenoceptors in mammalian atrial and ventricular myocardium. Eur J Pharmacol (1993) 0.85
Adenosine A1 receptor-dependent and -independent effects of the allosteric enhancer PD 81,723. J Pharmacol Exp Ther (1999) 0.85
Influence of age and smoking on drug kinetics in man: studies using model compounds. Clin Pharmacokinet (1980) 0.85
Evaluation of docetaxel in previously untreated extensive-stage small cell lung cancer: a Southwest Oncology Group phase II trial. Cancer J Sci Am (1999) 0.85
Sarcoplasmic reticulum calcium release is stimulated and inhibited by daunorubicin and daunorubicinol. Toxicol Appl Pharmacol (2000) 0.84